Diagnosis of Militarily Relevant Diseases Using Oral Fluid and Saliva Antibodies: Fluorescence Polarization Immunoassay

Military Medicine

Volumn 168, Issue 11, 2003, Pages 915-921

  Cullum, Malford E ^a   Lininger, Linda A ^a   Schade, Sylvia Z ^a   Cope, Stanton E ^a   Ragain Jr , James C ^a   Simonson, Lloyd G ^a  

^a Dental and Biomedical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBODY; IMMUNOGLOBULIN; MYCOBACTERIUM VACCINE;

ANTHRAX; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; BACTERIUM DETECTION; BCG VACCINATION; BLOOD CELL; CHEMOLUMINESCENCE; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; LUNG TUBERCULOSIS; MEDICAL RESEARCH; METHODOLOGY; MILITARY MEDICINE; MOLECULAR INTERACTION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; REVIEW; SALIVA ANALYSIS; SCREENING TEST; SEPARATION TECHNIQUE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0345307807     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/168.11.915     Document Type: Review

References (95)

1. Anonymous: Biography on Saliva. Library of Congress Bibliography Section Science and Technology Division: Office of Naval Research report ACR-48, Washington, DC. Library of Congress, 1960.
2. Kraus F, Konno J: The salivary secretion of antibody. Alabama J Med Sci 1965; 2: 15-22.
3. Hirschman JD, Kresge JA: Synthesis of a symposium: innovative non- of minimally-invasive technologies for monitoring health and nutritional status in mothers and young children. J Nutr 2001; 131: 1643S-5S.
4. Hofman LF: Human saliva as a diagnostic specimen. J Nutr 2001; 131: 1621S-5S.
5. Tenovuo J: Human Saliva: Clinical Chemistry and Microbiology, Vol 1, p 256. Boca Raton, FL, CRC Press, 1989.
6. Saliva in health and disease: Proceedings of the 16th International Conference on Oral Biology, April 9-12, 2000, Chantilly, Virginia, USA. Adv Dent Res 2000; 14: 5-102.
7. Kaufman E, Lamster IB: Analysis of saliva for periodontal diagnosis: a review. J Clin Periodontol 2000; 27: 453-65.
8. Streckfus CF, Bigler LR: Saliva as a diagnostic fluid. Oral Dis 2002; 8: 69-76.
9. Rossomando EF, Kousvelari E, Janicki BW, Tabak LA: Improvement of oral health in the postgenomic era: opportunities for government/industry partnerships. Compend Contin Educ Dent 2001; 22: 570-2, 574.
10. Tabak LA: A revolution in biomedical assessment: the development of salivary diagnostics. J Dent Educ 2001; 65: 1335-9.
11. Cordeiro ML, Turpin CS, McAdams SA: A comparative study of saliva and OraSure oral fluid. Ann N Y Acad Sci 1993; 694: 330-1.
12. Rehak NN, Cecco SA, Csako G: Biochemical composition and electrolyte balance of "unstimulated" whole human saliva. Clin Chem Lab Med 2000; 38: 335-43.
13. Soderling E: Practical Aspects of Salivary Analysis, Human Saliva: Clinical Chemistry and Microbiology, Vol 1, pp 1-24. Boca Raton, FL, CRC Press, 1989.
14. Seymour E: Salivary sampling device and sample adequacy system: Patent 5,393,496, Vancouver, WA. Patent and Trademark Office, United States, Salivary Diagnostic Systems, 1995.
15. Goldstein AS, Gadojdea S, Zogg DF: Oral collection device and method for immunoassay: Patent 5,335,673, Beaverton, OR. Patent and Trademark Office, United States, Epitope, Inc., 1994.
16. McKie A, Vyse A, Maple C: Novel methods for the detection of microbial antibodies in oral fluid. Lancet Infect Dis 2002; 2: 18-24.
17. Marcus ER, Jooste CP, Driver HS, Hattingh J: The quantification of individual proteins in crevicular gingival fluid. J Periodontal Res 1985; 20: 444-9.
18. Burke JC, Evans CA, Crosby TR, Mednieks MI: Expression of secretory proteins in oral fluid after orthodontic tooth movement. Am J Orthod Dentofacial Orthop 2002; 121: 310-5.
19. Slots J, Taubman MA; Contemporary Oral Microbiology and Immunology, p 649. St. Louis, MO, Mosby-Year Book, 1991.
20. Thieme TR, Goldstein AS, Piacentirii SC, Klimkow NM: Oral Collection Device and Kit: Patent 5,830,410, Beaverton, OR, Patent and Trademark Office, United States, Epitope, Inc., 1998.
21. Cimasoni G: The crevicular fluid. In Monographs in Oral Science, Vol 3, p 122. Basel, S. Karger, 1974.
22. Lehner T: The borderland between caries and periodontal disease. In Proceedings of a Conference Sponsored by the Royal Society of Medicine, February 28, 1977. London, Academic Press, Grune & Stratton, 1977.
23. Gallo D, George JR, Fitchen JH, Goldstein AS, Hindahl MS: Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing: OraSure HIV Clinical Trials Group. JAMA 1997; 277: 254-8.
24. Steenhuysen J: Orasure, Abbott agrees to co-distribute HIV test. Chicago, IL. Reuters, 2002.
25. Roitt IM, Lehner T: Immunology of Oral Diseases. pp 464. Oxford, UK, Blackwell Scientific Publications, 1981.
26. Thieme T, Piacentini S, Davidson S, Steingart K: Determination of measles, mumps, and rubella immunization status using oral fluid samples. JAMA 1994; 272: 219-21.
27. Bull AR, Kimmance KJ, Parry JV, Perry KR: Investigation of an outbreak of hepatitis A simplified by salivary antibody testing. Epidemiol Infect 1989; 103: 371-6.
28. Parry JV, Perry KR, Panday S, Mortimer PP: Diagnosis of hepatitis A and B by testing saliva. J Med Virol 1989; 28: 255-60.
29. Sherman KE, Creager RL, O'Brien J, Sargent S, Piacentini S, Thieme T: The use of oral fluid for hepatitis C antibody screening. Am J Gastroenterol 1994; 89: 2025-7.
30. Patel P, Mendall M, Khulusi S, et al: Salivary antibodies to Helicobacter pylori screening dyspeptic patients before endoscopy. Lancet 1994; 344: 511-4.
31. Parry JV, Perry KR, Mortimer PP: Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. Lancet 1987; 2: 72-5.
32. Barros M, Duarte Neto AN, Pereira VR, et al: Evaluation of oral mucosal transudate for immunodiagnosis of chagas' disease. Rev Inst Med Trop Sao Paulo 1999; 41: 265-6.
33. Dandliker W, Feigen G: Quantification of the antigen-antibody reaction by the polarization of fluorescence. Biochem Biophys Res Commun 1961; 5: 299-304.
34. Perrin F: Polarization de la Iumiere de fluorescence: vie moyenne de molecules dans l'etat excite. J Phys Radium 1926; 7: 390-401.
35. Skoog DA, Leary JJ: Principles of Instrumental Analysis, p 700. Fort Worth, TX, Saunders College Publishing, 1992.
36. Keren DF, Warren JS: Diagnostic Immunology, p 402. Baltimore, MD, Williams & Wilkins, 1992.
37. Popelka SR: Optical apparatus for fluorescence polarization instrument: Patent 4,516,856, North Chicago IL, Patent and Trademark Office, United States, Abbott Laboratories, 1985.
38. Erwin P: Apparatus and method for measuring the magnitude of polarization of light: Patent 4,269,511, North Chicago IL. Patent and Trademark Office, United States, Abbott Laboratories, 1981.
39. Novitsky TJ, Sloyer J, John L, Elias ER, Shinn A, Fan C: Liquid crystal polarizer for a device for measuring fluorescence polarization: Patent D443,216, Falmouth MA, Patent and Trademark Office, United States. Associates of Cape Cod. Inc., 2001.
40. Allen M, Reeves J, Mellor G: High throughput fluorescence polarization: a homogeneous alternative to radioligand binding for cell surface receptors. J Biomol Screen 2000; 5: 63-9.
41. Nasir M, Jolley M: Fluorescence polarization: an analytical tool for immunoassay and drug discovery. Comb Chem High Throughput Screen 1999; 2: 177-90.
42. Kowski T, Wu J: Fluorescence polarization is a useful technology for reagent reduction in assay miniaturization. Comb Chem High Throughput Screen 2000; 3: 437-44.
43. ONR: Future Naval Capabilities: Warfighter Protection. Washington DC, Department of the Navy, Science and Technology Lead, 1992.
44. Terpetschnig E, Szmacinski H, Lakowicz J: Fluorescence polarization immunoassay of a high-molecular-weight antigen based on a long-lifetime Ru-ligand complex. Anal Biochem 1995; 227: 140-7.
45. Tencza S, Islam K, Kalia V, Nasir M, Jolley M, Montelaro R: Development of a fluorescence polarization-based diagnostic assay for equine infectious anemia virus. J Clin Microbiol 2000; 38: 1854-9.
46. Schade S, Jolley M: Fluorescence polarization assays of enzymes and substrates thereof: Patent 5,804,395, Washington, DC, Patent and Trademark Office, United States, Secretary of the Navy, 1998.
47. Schade S, Jolley M, Sarauer B, Simonson L: BODIPY-α-casein, a pH-independent protein substrate for protease assays using fluorescence polarization. Anal Biochem 1996; 243: 1-7.
48. Gunderson EK, Garland C, Hourani LL: Infectious disease rates in the U.S. Navy, 1980 to 1995. Milit Med 2001; 166: 544-9.
49. Behr MA, Wilson MA, Gill WP, et al: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-3.
50. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM: A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804-9.
51. Ashford D, Rotz L: Use of anthrax vaccine in the United States. Morb Mortal Wkly Rep 2000; 49: 1-20.
52. Nasir M, Jolley M: Fluorescence polarization: stretching it to its limits: a special edition on fluorescence polarization. Comb Chem High Throughput Screen 2002, 2003; 6: 167-273.
53. Jolley M: Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol 1981; 5: 236-40.
54. Lin M, Sugden E, Jolley M, Stilwell K: Modification of the Mycobacterium bovis extracellular protein MPB70 with fluorescein by fluorescence polarization. Clin Diag Lab Immunol 1996; 3: 438-43.
55. Nielsen K, Gall D, Jolley M, et al: A homogeneous fluorescence polarization assay for detection of antibody to Brucella abortus. J Immunol Methods 1996; 195: 161-8.
56. Forkey JN, Quinlan ME, Goldman YE: Protein structural dynamics by single-molecule fluorescence polarization. Prog Biophys Mol Biol 2000; 74: 1-35.
57. Van Dyke K, Castranova V: Cellular Chemiluminescence, Vol 1-3. Boca Raton, FL, CRC Press, 1987.
58. Wier ML: Methods for measurement of lymphocyte function: Patent 5,773,232, Columbia, MD, Patent and Trademark Office, United States, Biotechnology Transfer, Inc., 1998.
59. Arai R, Nakagawa H, Tsumoto K, et al: Demonstration of a homogeneous noncompetitive immunoassay based on bioluminescence resonance energy transfer. Anal Biochem 2001; 289: 77-81.
60. Ullman EF, Kirakossian H, Pease JS, Daniloff Y, Wagner DB: Assay method utilizing induced luminescence: Patent 6,406,913, Marburg, DE, Patent and Trademark Office, United States, Dade Behring Marburg GmbH, 2002.
61. Sellman B, Mourez M, Collier R: Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 2001; 292: 695-7.
62. Petosa C, Collier R, Klimpel K, Leppla S, Liddington R: Crystal structure of the anthrax toxin protective antigen. Nature 1997; 385: 833-8.
63. Little SF, Novak J, Lowe J, et al: Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 1996; 142: 707-15.
64. Brossier F, Sirard J-C, Guidi-Rontani C, Duflot E, Mock M: Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect Immunol 1999; 67: 964-7.
65. Brossier F, Weber-Levy M, Mock M, Sirard J: Role of toxin functional domains in anthrax pathogenesis. Infect Immunol 2000; 68: 1781-6.
66. Mogridge J, Moourez M, Collier R: Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J Bacteriol 2001; 183: 2111-6.
67. Brachman P, Gold H, Plotkin S, Fekety F, Werrin M, Ingraham N: Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52: 632-45.
68. Fellows P, Linscott M, Ivins B, et al: Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19: 3241-7.
69. Turnbull P, Broster M, Carman J, Manchee R, Melling J: Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immunol 1986; 52: 356-63.
70. Reuveny S, White M, Adar Y, et al: Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immunol 2001; 69: 2888-93.
71. McBride B, Mogg A, Telfer J, et al: Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16: 810-7.
72. Wilkins E, Bothamley G, Jackett P: A rapid, simple enzyme immunoassay for detection of antibody to individual epitopes in the serodiagnosis of tuberculosis. Eur J Clin Microbiol Infect Dis 1991; 10: 559-63.
73. Andersen A, Hansen E: Structure and mapping of antigenic domains of protein antigen b. a 38,000-molecular-weight protein of Mycobacterium tuberculosis. Infect Immunol 1989; 57: 2481-8.
74. Brosch R, Gordon SV Marmiesse M, et al: A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002; 99: 3684-9.
75. Wilkinson R, Haslov K, Rappuoli R, et al: Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. J Clin Microbiol 1997; 35: 553-7.
76. Colangeli R, Heijbel A, Williams A, et al: Three-step purification of lipopolysaccharide-free, polyhistidine-tagged recombinant antigens of Mycobacterium tuberculosis. J Chromatogr B Biomed Sci Appl 1998; 714: 223-35.
77. Singh M, Andersen A, McCarthy J, et al: The Mycobacterium tuberculosis 38-kDa antigen: overproduction in Escherichia coli, purification and characterization. Gene 1992; 117: 53-60.
78. Cullum ME, Schade SZ, Simonson LG, Lininger LA, Lewis AS: Immunoassay of 16 and 38 kDa Antigens from Mycobacterium tuberculosis H37Rv. Orlando, FL, American Society for Microbiology 101st General Meeting. May 19-25, 2001.
79. Lyashchenko K, Colangeli R, Houde M, Jahdali H, Menzies D, Gennaro M: Heterogeneous antibody responses in tuberculosis. Infect Immunol 1998; 66: 3936-40.
80. Struyf F, Lemmens A, Valadas E, Verhaegen J, Van Ranst M: Usefulness of immunochromatographic detection of antibodies to Mycobacterium tuberculosis as an adjunct to auramine staining for rapid diagnosis of tuberculosis in a low-prevalence setting. Eur J Clin Microbiol Infect Dis 1999; 18: 740-2.
81. Cole ST, Brosch R, Parkhill J, et al: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
82. Price LB, Hugh-Jones M, Jackson PJ, Keim P: Genetic diversity in the protective antigen gene of Bacillus anthracis. J Bacteriol 1999; 181: 2358-62.
83. Challacombe SJ, Russell MW, Hawkes JE, Bergmeier LA, Lehner T: Passage of immunoglobulins from plasma to the oral cavity in rhesus monkeys. Immunology 1978; 35: 923-31.
84. Jackson S, Mestecky J, Moldoveanu Z, Spearman P: Collection and Processing of Human Mucosal Secretions. Mucosal Immunology, pp 1567-75. New York, Academic Press, 1998.
85. Granade TC, Phillips SK, Kitson-Piggott W, et al: Influence of host factors on immunoglobulin G concentration in oral fluid specimens. Clin Diagn Lab Immunol 2002; 9: 194-7.
86. Nagler RM, Hershkovich O, Lischinsky S, Diamond E, Reznick AZ: Saliva analysis in the clinical setting: revisiting an underused diagnostic tool. J Invest Med 2002; 50: 214-25.
87. Roitt IM, Lehner T: Immunological aspects of oral diseases. In Immunology of Oral Diseases, pp 297-332. Oxford, UK, Blackwell Scientific Publications, 1981.
88. Cuzzubbo AJ, Vaughn DW, Nisalak A, Suntayakorn S, Aaskov J, Devine PL: Detection of specific antibodies in saliva during dengue infection. J Clin Microbiol 1998; 36: 3737-9.
89. Seilles E, Rossel M, Vuitton DA, et al: Serum secretory IgA and secretory component in patients with non-cirrhotic alcoholic liver diseases. J Hepatol 1995; 22: 278-85.
90. Proctor GB, Carpenter GH: Chewing stimulates secretion of human salivary secretory immunoglobulin A. J Dent Res 2001; 80: 909-13.
91. Gomez FE, Villegas J, Bourges H: An enzyme-linked immunosorbent assay for human secretory immunoglobulin A in parotid saliva. Rev Invest Clin 1991; 43: 351-8.
92. Smith D: The oral cavity as an immunological entity. In Contemporary Oral Microbiology and Immunology, p 649. St. Louis, MO, Mosby-Year Book, 1991.
93. Voltz JM, Mole C, Aubin F, et al: [Serum and salivary immunoglobins A in atopic dermatitis: prospective and comparative case control study]. Ann Dermatol Venereol 1998; 125: 100-4.
94. Bothamley G, Beck J, Schreuder G, et al: Association of tuberculosis and Mycobacterium tuberculosis-specific antibody levels with HLA. J Infect Dis 1989; 159: 549-55.
95. Dillon DC, Alderson MR, Day CH, et al: Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol 2000; 38: 3285-90.